Skip to main content
Clinical Trials/IRCT20090117001556N138
IRCT20090117001556N138
Not yet recruiting
Phase 2

Investigating the effect of Famotidine on cognitive and behavioral dysfunctions induced by COVID-19: A randomized double blind and placebo controlled clinical trial

Tehran University of Medical Sciences0 sites50 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
COVID-19.
Sponsor
Tehran University of Medical Sciences
Enrollment
50
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • History of hospitalization due to COVID\-19
  • At least 20 days from the onset of symptoms, and 7 days from the last day of symptoms passed
  • Diagnosis of cognitive impairment (score 23 or less in MMSE test, or score 22 or less in MoCA test)
  • Age between 18\-65

Exclusion Criteria

  • Being psychotic
  • Presence of other psychiatric disorders
  • Using other psychiatric drugs or any drug which can affect cognitive performance
  • History of ECT during past 2 months
  • Presence of thyroid disease
  • Presence of kidney disease
  • Presence of liver disease
  • History of cognitive impairment or dementia
  • Pregnant or lactating women

Outcomes

Primary Outcomes

Not specified

Similar Trials